Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts

被引：32
|
作者：
van der Helm, L. H. [1 ]
Veeger, N. J. G. M. [1 ]
van Marwijk Kooy, M. [2 ]
Beeker, A. [3 ]
de Weerdt, O. [4 ]
de Groot, M. [5 ]
Alhan, C. [6 ]
Hoogendoorn, M. [7 ]
Laterveer, L. [8 ]
van de Loosdrecht, A. A. [6 ]
Koedam, J. [9 ]
Vellenga, E. [1 ]
Huls, G. [1 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, NL-9713 GZ Groningen, Netherlands
[2] Isala Klin, Dept Internal Med, Zwolle, Netherlands
[3] Spaarne Ziekenhuis, Dept Internal Med, Hoofddorp, Netherlands
[4] St Antonius Hosp, Dept Internal Med, Nieuwegein, Netherlands
[5] Med Spectrum Twente, Dept Internal Med, Enschede, Netherlands
[6] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands
[7] Med Ctr Leeuwarden, Dept Hematol, Leeuwarden, Netherlands
[8] Diaconessenhuis, Dept Internal Med, Meppel, Netherlands
[9] Celgene BV, Utrecht, Netherlands
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷 / 08期
关键词：
Acute myeloid leukemia; Older age; Azacitidine; Bone marrow blast count; Predictors; ACUTE MYELOID-LEUKEMIA; INTERNATIONAL WORKING GROUP; CONVENTIONAL CARE REGIMENS; ELDERLY-PATIENTS; MYELODYSPLASTIC SYNDROMES; RESPONSE CRITERIA; OLDER PATIENTS; PHASE-III; AGE; CLASSIFICATION;
D O I：
10.1016/j.leukres.2013.03.022
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The efficacy of azacitidine has been demonstrated in acute myeloid leukemia (AML) patients with 20-30% bone marrow (BM) blasts, but limited data is available on patients with >= 30% blasts. We analyzed 55 newly diagnosed AML patients, treated with azacitidine. The overall response rate was 42%. Median overall survival (OS) was 12.3 months. We confirmed poor-risk cytogenetics, therapy-related AML, performance score >= 2, and white blood cell count >= 15x10(9)/L as independent adverse predictors for OS. The BM blast percentage, however, had no impact on OS (P=0.55). In conclusion, administration of azacitidine is effective in AML patients with 20-30% and >30% BM blasts. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码：877 / 882
页数：6
相关论文
共 50 条
  • [41] Azacitidine in Acute Myeloid Leukemia with >30% Bone Marrow Blasts and <15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data
    Pleyer, Lisa
    Burgstaller, Sonja
    Stauder, Reinhard
    Girschikofsky, Michael
    Sill, Heinz
    Schlick, Konstantin
    Thaler, Josef
    Halter, Britta
    Machherndl-Spandl, Sigrid
    Zebisch, Armin
    Pichler, Angelika
    Pfeilstoecker, Michael
    Autzinger, Eva-Maria
    Lang, Alois
    Geissler, Klaus
    Voskova, Daniela
    Geissler, Dietmar
    Sperr, Wolfgang R.
    Hojas, Sabine
    Rogulj, Inga Mandac
    Andel, Johannes
    Greil, Richard
    BLOOD, 2015, 126 (23)
  • [42] Amlodipine Increases Vitamin D Levels More Than Valsartan in Newly Diagnosed Hypertensive Patients: Pointing to an Additional Effect on Bone Metabolism or a Novel Marker of Inflammation?
    Ay, Seyit Ahmet
    Karaman, Murat
    Cakar, Mustafa
    Balta, Sevket
    Arslan, Erol
    Bulucu, Fatih
    Demirbas, Seref
    Celik, Turgay
    Naharci, Mehmet Ilkin
    Demirkol, Sait
    Kurt, Omer
    Bozoglu, Ergun
    RENAL FAILURE, 2013, 35 (05) : 691 - 696
  • [43] Response-Adapted Sequential Treatment with Azacitidine and Intensive Chemotherapy in Patients >60 Years Old with Newly Diagnosed AML: Results of the RAS-Azic Trial of the East German Study Group (OSHO)
    Jaekel, Nadia
    Hubert, Karolin
    Krahl, Rainer
    Haenel, M.
    Maschmeyer, Georg
    Herbst, Regina
    Jakob, Christian
    Schulze, Susann
    Wang, Song-Yau
    Cross, Michael
    Kahl, Christoph
    Wass, Maxi
    Sayer, Herbert G.
    Brosteanu, Oana
    Niederwieser, Dietger
    Al-Ali, Haifa Kathrin
    BLOOD, 2017, 130
  • [44] Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): Results of the Phase I of the DRKS00004519 Study
    Al-Ali, Haifa Kathrin
    Krahl, Rainer
    Cross, Michael
    Karolin, Hubert
    Jaekel, Nadja
    Niederwieser, Dietger
    BLOOD, 2014, 124 (21)
  • [45] Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients
    Jia, Bei
    Wang, Liru
    Claxton, David F.
    Ehmann, W. Christopher
    Rybka, Witold B.
    Mineishi, Shin
    Rizvi, Syed
    Shike, Hiroko
    Bayerl, Michael
    Schell, Todd D.
    Hohl, Raymond J.
    Zheng, Hong
    BLOOD CANCER JOURNAL, 2018, 8
  • [46] Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients
    Bei Jia
    Liru Wang
    David F. Claxton
    W Christopher Ehmann
    Witold B. Rybka
    Shin Mineishi
    Syed Rizvi
    Hiroko Shike
    Michael Bayerl
    Todd D. Schell
    Raymond J. Hohl
    Hong Zheng
    Blood Cancer Journal, 8
  • [47] PD1 expression on bone marrow T-cells in newly diagnosed Egyptian AML patients: Correlation with hematological parameters, aberrant antigens expression, and response to induction therapy
    Bassiouny, Noha
    El-Hoda, Nour
    Khalifa, Ibtesam M.
    Ibrahim, Sara
    Salem, Lamyaa
    Annaka, Layla
    EJHAEM, 2020, 1 (01): : 51 - 57
  • [48] Response-adapted sequential azacitidine and induction chemotherapy in patients >60 years old with newly diagnosed AML eligible for chemotherapy. Results of the DRKS00004519 study of the East German Study Group
    Jaekel, N.
    Hubert, K.
    Krahl, R.
    Hanel, M.
    Maschmeyer, G.
    Herbst, R.
    Jakob, C.
    Schulze, S.
    Wang, S. -Y.
    Cross, M.
    Kahl, C.
    Wass, M.
    Sayer, H. G.
    Brosteanu, O.
    Niederwieser, D.
    Al-Ali, H. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 27 - +
  • [49] Response-adapted sequential azacitidine and induction chemotherapy in patients >60 years old with newly diagnosed AML eligible for chemotherapy (RAS-AZIC): Results of the phase I of the DRKS00004519 study
    Jaekel, N.
    Hubert, K.
    Krahl, R.
    Cross, M.
    Niederwieser, D.
    Al-Ali, H. K.
    Oncology Research and Treatment, 2015, 38 : 47 - 47
  • [50] Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study
    DiNardo, Courtney D.
    Schuh, Andre C.
    Stein, Eytan M.
    Fernandez, Pau Montesinos
    Wei, Andrew
    De Botton, Stephane
    Zeidan, Amer M.
    Fathi, Amir T.
    Quek, Lynn
    Kantarjian, Hagop M.
    Frattini, Mark G.
    Lersch, Frederik
    Gong, Jing
    Franovic, Aleksandra
    MacBeth, Kyle
    Vyas, Paresh
    Dohner, Hartmut
    BLOOD, 2019, 134
12345